Evaluating the Effect of Bone Morphogenetic Protein on Dental Implant Stability and Marginal Bone Level Following Immediate Implant Placement (Randomized Controlled Clinical Study)

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Background: Immediate implant placement has become a widely accepted treatment modality because of reduced treatment time and preservation of alveolar bone architecture. Recombinant human bone morphogenetic protein-2 (rhBMP-2) has been proposed to enhance peri-implant bone regeneration and implant stability. This study evaluated the effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) combined with biphasic calcium phosphate graft on implant stability and peri-implant bone preservation following immediate implant placement. Methods: Twenty-four patients who received 32 immediate dental implants were randomly assigned to 2 groups. The control group received a biphasic calcium phosphate graft alone in the jumping gap, whereas the study group received the graft combined with 0.1 mg rhBMP-2. Implant stability, marginal bone level, and buccal bone thickness were evaluated clinically and radiographically over 16 weeks. Results: Thirty implants were analyzed. Both groups showed a significant increase in implant stability over 16 weeks. The control group demonstrated a slightly higher relative percentage increase than the study group (11.17%±4.34 versus 9.57%±3.83), with no statistically significant difference between groups ( P =0.637). No statistically significant differences were observed regarding marginal bone loss or buccal bone thickness changes at 1 mm and 2 mm below the implant screw ( P >0.05). Conclusions: The addition of rhBMP-2 to a biphasic calcium phosphate graft did not confer significant clinical advantages over the graft alone following immediate dental implant placement, suggesting limited additional benefit relative to its cost.